Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020538 (hypertension)
 170,190 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The antihypertensive efficacy and the acceptability of nifedipine (NI, Adalat) and the usefulness of its combination with a beta 1-selective blocking drug, acebutolol (AC), were studied in a placebo controlled trial on 15 patients with moderate hypertension. The study consisted of three phases: 1. An acute test, including the single blind comparison of three different single doses of NI (5, 10, 20 mg), alone and in combination with AC 200 mg, with placebo and with AC alone (200 mg), showed an early hypotensive effect, with no differences for the three doses of NI, reaching the maximum between 50 and 240 min, greater than the one of AC, and smaller in comparison with the one of the combinations, which didn't differ at the three doses of NI. Heart rate (HR) and side effects, instead, increased with the increasing doses of NI, suggesting a worse acceptability for the greater doses. 2. A long-term treatment, including a double-blind comparison of three separate periods of 4 weeks of treatment with NI (10 mg three times a day), AC (200 mg three times a day) and with the combination of the same doses, showed a significant reduction of systolic and diastolic blood pressure (BP) for each treatment, not significantly different at rest for the three single drugs but greater for the combined treatment, assuring also a better control of systolic BP during exercise. A reduced number of side effects was seen with the combined therapy which seems to contribute to a better compliance.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Acebutolol and nifedipine in the treatment of arterial hypertension: efficacy and acceptability. 638 7

The present study was aimed to evaluate the acute and chronic hypotensive effects of nifedipine (Bay a 1040, Adalat) and niludipine (Bay a 7168) in hypertensive patients with chronic renal failure. 1. The decrease of blood pressure lasted for at least 3 h and maximum decrement was achieved in 60 min (26% decrement, p less than 0.05) after oral administration of nifedipine (10 mg). On the other hand, niludipine (20 mg) caused decrease of blood pressure for at least 4 h and attained maximum decrement in 90 min (13% decrement, p less than 0.05) after oral administration. 2. In chronic studies of both drugs, the maximum decrease of blood pressure (p less than 0.05) was attained after one week and lasted at least 4 weeks. There were no significant changes of pulse rate, body weight and urine volume in both nifedipine and niludipine groups. 3. Nifedipine caused great diurnal or day-to-day fluctuations of blood pressures after chronic administrations. On the other hand niludipine did not cause any significant fluctuations. Any serious complications could not be seen during these studies. In conclusion, these results provide clinical evidence that niludipine could be usefused great diurnal or day-to-day fluctuations of blood pressures after chronic administrations. On the other hand niludipine did not cause any significant fluctuations. Any serious complications could not be seen during these studies. In conclusion, these results provide clinical evidence that niludipine could be useful for treatment of hypertension associated with chronic renal failure. Results also suggest that the optimal efficacy of nifedipine and niludipine in part depends on the specific clinical situation at hand. For example, nifedipine seems to be the drug of choice in hypertensive emergencies when there is a need for rapid lowering of blood pressure.
 ...
PMID:Acute and chronic hypotensive effects of nifedipine and niludipine in hypertensive patients with chronic renal failure. 643 1

The antihypertensive effect of nifedipine (Adalat), a Ca2+-antagonistic drug, was studied in patients with mild or severe hypertension. In both short- and long-term trials, nifedipine exerted a strong hypotensive effect, more pronounced in patients with severe than in cases with mild hypertension. The results of our short-term study showed a positive correlation between the maximum fall in blood pressure induced by nifedipine and pretreatment systolic blood pressure values or the total severity index score of hypertension. In our long-term trial, we also observed a positive correlation between maximum reduction of blood pressure--induced by nifedipine--and pretreatment values. However, no correlation between reduction of blood pressure and total severity index score of hypertension could be established. Our results indicate that nifedipine could be effective in the management of severe hypertension. The hypotensive action of nifedipine, at least partly due to its Ca2+ influx blocking action, suggests that etiologically hypertension may be connected with an abnormal calcium metabolism of the cardiovascular muscle cells.
 ...
PMID:Antihypertensive effect of nifedipine and its relationship to severity of hypertension. 668 66

The hypotensive effect of 4-(2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxydimethylester (nifedipine, Adalat) was studied in 15 hypertensive patients with chronic renal failure. The decrease of blood pressure lasted for approximately 3 h and maximum decrement was achieved in 1 h after oral administration of nifedipine (10 mg). Hypotensive action of the drug was associated with a constant decrease in total peripheral resistance and an increase in cardiac output, plasma renin activity (PRA), and plasma norepinephrine (noradrenaline). Initial PRA was apparently the major determinant of the rise in PRA since a close correlation was present between the initial value and the increase induced by nifedipine (r = 0.93, p less than 0.05). Marked reduction of blood pressure without noticeable side effects was observed in two cases who had not responded to previous antihypertensive treatment. These data suggest that nifedipine exerts its hypotensive action through peripheral vasodilation and may be an effective drug for treatment of hypertension during chronic renal failure.
 ...
PMID:Hypotensive effect of nifedipine in hypertensive patients with chronic renal failure. 676 Aug 69

The aim of the study was to evaluate chronic treatment with Cordafen (nifedipine) in the out-patients over 60 years of age with established arterial hypertension. Out of 100 out-patients aged 60-83 years 69 subjects completed one-year study. The main reasons of drop-outs were: lack of patient compliance (12%), severe side effects (11%), ineffective monotherapy (5%) and other (3%). Less severe adverse effects were found in further 20 subjects. After one-year therapy hematological and biochemical parameters of the homeostasis did not deteriorate except an increase in alkaline phosphatase. Regular drug intake in a dose of 20-80 mg/daily (mean = 46.0) produced a significant decrease in the blood pressure level and an improvement of cardiac function indices (CO nad EF). In contrast Cordafen did not reduce the differences between extreme blood pressure values recorded automatically, and it did not produce a significant regression of left ventricular mass and cardiac arrhythmias. Nifedipine in mild or moderate hypertension in the elderly patient any be an adequate form of monotherapy in about 70% of them. Higher motivation for treatment in this age group and better drug tolerance may further improve this efficacy.
 ...
PMID:[Use of nifedipine in elderly patients with essential hypertension: patient compliance, safety and efficacy of therapy]. 786 85

We studied the therapeutic substitution of a less expensive but equally effective antihypertensive agent and assessed patient outcome. The medication of 39 patients with hypertension was changed from once-daily diltiazem hydrochloride (Cardizem CD) or nifedipine (Procardia XL) to felodipine (Plendil). Titration to a final dose was based on home and office blood pressure measurements assessed over subsequent follow-up clinic visits. Self-administered questionnaires measured different aspects of well-being and symptoms before and after the change in medication. Eighty percent of the cohort switched successfully to felodipine. Office systolic and diastolic pressures improved after the medication change (systolic: 150 mm Hg versus 144 mm Hg; diastolic: 92 mm Hg versus 87 mm Hg). No statistically significant differences were found among the 39 symptoms measured. A yearly savings potential for our institution was estimated to be $72,000.
 ...
PMID:Felodipine as an alternative to more expensive calcium antagonists in mild to moderate hypertension. 863 95

Corinfar-retard (CR) was tried in 146 patients, the acute test was performed in 26 cases. The findings confirm antihypertensive activity of the drug, reduced frequency of sharp changes in blood pressure and of hypertensive crises, side effects, its ability to diminish platelet aggregation. As for coronary heart disease. CR is more beneficial in non-severe angina of effort, spontaneous angina, associated hypertension. In hypertrophic cardiomyopathy prolonged administration of CR resulted in moderate subjective response. A CR two-month course did not induce noticeable changes in serum lipids. Hypertensive subjects on the acute test improved some hemodynamic and diastolic parameters.
 ...
PMID:[The use of the delayed-action form of korinfar in arterial hypertension, stenocardia and hypertrophic cardiomyopathy]. 864 29

Procardia XL Extended Release Tablets are being used with increasing frequency in the treatment of angina and hypertension. Bezoar formation, secondary to retained insoluble medication shells, is an important but less well-known complication. We report the first case of a small bowel bezoar due to this unique medication system.
 ...
PMID:Small bowel Procardia XL tablet bezoar mimicking cystic pneumatosis intestinalis. 866 59

Corinfar-retard as a base of different combinations with triampur, Cordanum, Capoten were studied in 52 patients with stable arterial hypertension (systolic pressure > 180 mm Hg, diastolic pressure > 105 mm Hg). In the above combinations pharmacokinetics of corinfar-retard did not change. Good response was noted in corinfar-retard combination with Cordanum in patients with moderate hemodynamic changes, hypertonicity of sympathoadrenal system, tachycardia. In patients with impaired myocardial contractility, elevated total peripheral vascular resistance, noticeable hypotensive effects was registered in combination with triampur. The absence of hypotensive effect in the above combination required the addition of Capoten which was absolutely indicated in patients with stable increase in plasma renin activity.
 ...
PMID:[The clinical efficacy of Korinfar-retard in combination with Cordanum, triampur and Capoten in patients with arterial hypertension]. 877 94

A surgical technique for treating nifedipine-induced gingival hyperplasia is described. A brief overview of nifedipine (trade name Procardia) is given, along with its use in the treatment of hypertension and its side effects, particularly as they relate to the induction of gingival hyperplasia. A detailed description and rationale for the surgical excision of the hyperplastic gingival tissue with a flap approach is given. A case is presented to illustrate the technique and post treatment results.
 ...
PMID:Surgical treatment of nifedipine-induced gingival hyperplasia. A case report. 900 33


<< Previous 1 2 3 4 5 6 Next >>